Olodanrigan (EMA401) is a highly selective, orally active, and peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. This compound is currently under development as a therapeutic agent for neuropathic pain. Its analgesic action is attributed to the inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, which effectively inhibits both DRG neuron hyperexcitability and the sprouting of DRG neurons.
- Highly selective AT2 receptor antagonist
- Orally active and peripherally restricted
- A therapeutic agent candidate for neuropathic pain
- Inhibits p38 and p42/p44 MAPK activation
- Prevents DRG neuron hyperexcitability and sprouting
- Purity of 98.9%
- Store powder at -20°C for 3 years or 4°C for 2 years
- Store in solvent at -80°C for 2 years or -20°C for 1 year